Class: Cerebrovascular System
Dosage Form: Tablets
Betahistine dihydrochloride………….8, 16, or 24 mg
Verserc is a histamine analogue.
Verserc increases the blood circulation in the stria vascularis of the inner ear, probably by means of a relaxation of the precapillary sphincters of the microcirculation of the inner ear.
Verserc reduces both frequency and the severity of the vertigo attacks, to have a favorable influence on tinnitus and to stop or partially reverse the progressive loss of hearing especially if treatment is started early.
Although progress can usually be seen within a few days, the onset of improvement is sometimes very gradual and clearly noticeable only after several weeks of treatment.
Betahistine hydrochloride is rapidly and completely absorbed after oral administration of the drug in tablet form. It is excreted almost quantitatively in urine as 2-pyridylacetic acid for 24 hours following administration. No unchanged betahistine has ben detected.
Verserc is indicated in vertigo, dizziness, tinnitus and /or progressive loss of hearing associated with Ménière’s disease and Ménière’s-like syndrome, usually accompanied also by nausea and vomiting.
Verserc is contraindicated in phaeochromocytoma.
Betahistine is generally well tolerated. In some cases mild gastric complaints have been observed, these can normally be dealt with by taking the dose during meals.
Dosage and Administration:
The following is generally recommended:
- Initially: 48 mg daily in divided doses
- Maintenance: 24-48 mg daily in divided doses
As optimal results are usually obtained after few months, prolonged treatment is recommended.
Pregnancy and Lactation:
There is insufficient data on the use of this drug during pregnancy to evaluate possible harmful effects. There are no indications for harmful effects in animal testing.
Patients with bronchial asthma or peptic ulcer should be treated with caution.
Pack of 3 strips of 10 tablets each.
Store in a dry place at a temperature not exceeding 30°C.